Stifel Sees Accelerated Approval for Denali Therapeutics Inc.'s (DNLI) DNL310
Tweet Send to a Friend
Stifel analyst Paul Mattels reiterated a Buy rating and $37.00 price target on Denali Therapeutics Inc. (NASDAQ: DNLI).The analyst commented ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
